TIP25-242: The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients With Ductal Carcinoma In Situ
"TIP25-242: The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients With Ductal Carcinoma In Situ" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Authors
- Pat W. Whitworth (ORCID: https://orcid.org/0000-0002-6654-9990)
- Troy M. Bremer (ORCID: https://orcid.org/0000-0001-6100-605X)
- Rachel Rabinovitch
- Patrick I. Borgen
- Steven C. Shivers (ORCID: https://orcid.org/0000-0001-9538-4016)
- Anna E. Daily
Institutions
- Maimonides Medical Center (US)
- University of Colorado Cancer Center (US)
- PreludeDx (United States) (US)
- University of Tennessee at Knoxville (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-03-28
- DOI
- https://doi.org/10.6004/jnccn.2024.7241
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00